Enterococci constitute an important and diverse group of bacteria and have a complex association with human beings. Some of these species are used in food industry, while some others can cause various diseases in humans and animals (
1). Enterococci are Gram-positive bacteria constituting normal flora in birds, humans, and animals intestines, and they are found in the mouth cavity, intestine, and vagina of humans. They are the most abundant Gram-positive cocci in human faeces (
2). These microorganisms are the most common causes of hospital infections, particularly in ICU, the second agent in causing urine infection in hospitals, and the third agent in hospital bacteremia, endocarditis, and other infections among the ICU patients (
1,
3).
E. faecalis and
E. faecium are 2 common species isolated from nosocomial infections, and among the different species of enterococci that are currently recognized,
E. faecalis is responsible for 85% to 95% of enterococcal infections, while 5% to 10% of infections are caused by
E. faecium (
4). Enterococci are considered as a problematic bacteria in antibiotic treatments, as these bacteria resist against most antibiotics innately and can also acquire resistance through plasmids or transposons (
5). Hospital infections by enterococci is the main issue in hospitals, which is increasing in most countries including Iran (
6). Due to the inappropriate use of antibiotics in nosocomial infections, the resistance rate is increasing (
4). Aminoglycosides are frequently used in combination with cell wall active antibiotics for severe enterococcal infections. Unfortunately, enterococci with high-level resistance to aminoglycosides (HLAR) (MIC > 500 µg/mL) leads to the loss of synergy effect between a cell wall active agent and an aminoglycoside, typically gentamicin (
7).
Enterococcus species can acquire high-level resistance to a variety of antibiotics by horizontal transfer of mobile genetic determinants in addition to the intrinsic resistance to several groups of antimicrobials (
3). Resistance to the aminoglycosides usually occurs by enzymatic modification of the antibiotics by aminoglycoside-modifying enzymes (AME);
aac (6’)Ie-aph (2”)Ia is the most common gene causing HLGR in enterococci (
8). The first case of high-level gentamicin-resistant (HLGR)
E. faecalis isolate was reported by Thal et al. (1979) in France (
9). The resultant bifunctional
aac (6’)-aph (2”) aminoglycoside modifying enzyme confers resistance to all clinically useful aminoglycosides except streptomycin. The genes responsible for high-level aminoglycoside resistance have been identified on plasmids in most cases (
1). Murray and Hodel found that
aac (6’) Ie-aph (2”) Ia gene is located on transposon, Tn5281, whose presence on the transposon is a reason for rapid dispersion and high outbreak of HLGR in enterococci and increases the probability of horizontal transfer of the gene. Moreover, this gene is located on transposon Tn4001, which has been assigned to staphylococci, with similar transposon Tn4001 (
10). An increase in the prevalence of HLGR has been observed in European, Asian, and South American countries (
11).